Docality.com Logo
 
Dr. Ryan  Boone  Md image

Dr. Ryan Boone Md

5258 Dijon Dr
Baton Rouge LA 70808
225 691-1090
Medical School: Louisiana State University School Of Medicine In New Orleans - 1999
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: No
Participates In EHR: Yes
License #: 15385R
NPI: 1902891476
Taxonomy Codes:
207Y00000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Ryan Boone is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:70486 Description:Ct maxillofacial w/o dye Average Price:$550.00 Average Price Allowed
By Medicare:
$221.52
HCPCS Code:31575 Description:Diagnostic laryngoscopy Average Price:$350.00 Average Price Allowed
By Medicare:
$106.75
HCPCS Code:92550 Description:Tympanometry & reflex thresh Average Price:$80.00 Average Price Allowed
By Medicare:
$19.63
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$202.05 Average Price Allowed
By Medicare:
$150.03
HCPCS Code:92557 Description:Comprehensive hearing test Average Price:$85.00 Average Price Allowed
By Medicare:
$36.70
HCPCS Code:99203 Description:Office/outpatient visit new Average Price:$143.64 Average Price Allowed
By Medicare:
$97.55
HCPCS Code:70210 Description:X-ray exam of sinuses Average Price:$70.00 Average Price Allowed
By Medicare:
$28.68
HCPCS Code:69210 Description:Remove impacted ear wax Average Price:$85.00 Average Price Allowed
By Medicare:
$47.31
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$125.00 Average Price Allowed
By Medicare:
$97.17
HCPCS Code:95115 Description:Immunotherapy one injection Average Price:$25.00 Average Price Allowed
By Medicare:
$8.61
HCPCS Code:J1040 Description:Methylprednisolone 80 MG inj Average Price:$22.69 Average Price Allowed
By Medicare:
$6.77
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$80.00 Average Price Allowed
By Medicare:
$65.54
HCPCS Code:95165 Description:Antigen therapy services Average Price:$23.97 Average Price Allowed
By Medicare:
$11.55
HCPCS Code:J0696 Description:Ceftriaxone sodium injection Average Price:$7.00 Average Price Allowed
By Medicare:
$0.79
HCPCS Code:J0702 Description:Betamethasone acet&sod phosp Average Price:$9.00 Average Price Allowed
By Medicare:
$5.55
HCPCS Code:96372 Description:Ther/proph/diag inj sc/im Average Price:$20.00 Average Price Allowed
By Medicare:
$20.00

HCPCS Code Definitions

96372
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
95115
Professional services for allergen immunotherapy not including provision of allergenic extracts; single injection
J0696
Injection, ceftriaxone sodium, per 250 mg
70210
Radiologic examination, sinuses, paranasal, less than 3 views
69210
Removal impacted cerumen requiring instrumentation, unilateral
31575
Laryngoscopy, flexible fiberoptic; diagnostic
95165
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; single or multiple antigens (specify number of doses)
92557
Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)
99203
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent face-to-face with the patient and/or family.
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
70486
Computed tomography, maxillofacial area; without contrast material
J1040
Injection, methylprednisolone acetate, 80 mg
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
J0702
Injection, betamethasone acetate 3mg and betamethasone sodium phosphate 3mg
92550
Tympanometry and reflex threshold measurements

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1336143841
Cardiovascular Disease (Cardiology)
375
1871525436
Internal Medicine
169
1902807233
Cardiovascular Disease (Cardiology)
158
1295786655
Internal Medicine
154
1457309759
Orthopedic Surgery
151
1275522328
Dermatology
144
1720088529
Geriatric Medicine
139
1891749602
Diagnostic Radiology
132
1134282957
Otolaryngology
124
1518962984
Cardiovascular Disease (Cardiology)
109
*These referrals represent the top 10 that Dr. Boone has made to other doctors

Publications

Modification of atrial natriuretic peptide receptor expression in the rat inner ear. - Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
The purpose of this animal study was to confirm the presence of all three atrial natriuretic peptide (ANP) receptor subtypes in the rat inner ear and compare the expression of each receptor after inner ear injection of ANP, phosphate-buffered saline, or a solution containing ANP incubated with anti-ANP antibody (to block upregulation).Receptors for ANP and related compounds have been localized in the inner ear of animals and humans. A previous study at this institution demonstrated the ability to up-regulate the expression of the three ANP receptors (ANP-A, ANP-B, ANP-C) in response to round window injection of ANP in the rat inner ear.After surgical exposure, the round window of female Lewis rats was injected with various concentrations of ANP, ANP plus anti-ANP antibody, or control. Animals were killed 24 hours after injection, inner ear tissues were harvested and homogenized, and RNA was isolated for reverse-transcription polymerase chain reaction.Electrophoresis showed the presence of all three receptor subtypes with exposure to phosphate-buffered saline. Expression was significantly higher 24 hours after injection with the two concentrations of ANP. This increase was partially blocked with increasing relative concentrations of anti-ANP antibody.These findings confirm the presence and responsiveness of ANP receptors in the rat inner ear. The ability to block up-regulation with the antibody provides a potential new research tool for manipulating the function of this hormone system in experimental models and, ultimately, in understanding the mechanisms of fluid homeostasis in the inner ear.
Failed newborn hearing screens as presentation for otitis media with effusion in the newborn population. - International journal of pediatric otorhinolaryngology
Evaluate the prevalence of middle ear disease in infants failing a newborn hearing screening program. Review the outcomes of those infants diagnosed with or without middle ear disease after failed hearing screen.Retrospective chart review of 76 patients referred to a tertiary care institution for evaluation of a failed newborn hearing screening test.Arkansas Children's Hospital, Little Rock, Arkansas.Seventy-six patients were referred for failed OAEs and complete otolaryngology evaluation. Mean age at the time of referral was 3 months (0.25 years) old. OME was identified in 64.5% of the patients. ABR confirmed a suspected hearing loss in 15 patients (78.9%) without middle ear disease. Effusion resolved without surgical intervention in 65.3% of infants, while 17 (34.7%) of the infants required tubes. SNHL was subsequently identified in 11% of infants after resolution of the effusion.OME is a common cause of failed infant hearing screens, and should be looked for prior to definitive diagnostic hearing testing. OME resolves in the majority of infants, but tube insertion is necessary to allow for diagnostic testing in nearly one third of infants. The majority of infants without OME had SNHL confirmed. SNHL was also identified in 11% of infants with OME after resolution of the effusion.
Success of cartilage grafting in revision tympanoplasty without mastoidectomy. - Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
Candidates for revision tympanoplasty have experienced at least one failed attempt at repair of the tympanic membrane and are, therefore, at higher risk for subsequent repair failure. The adjunctive use of mastoidectomy with tympanoplasty in those patients with noncholesteatomatous chronic otitis media is often used to decrease the risk for subsequent failure. However, at this institution, where we use cartilage tympanoplasty, mastoidectomy is rarely performed in the absence of cholesteatoma. Our objective was to assess outcomes in patients undergoing revision tympanoplasty without mastoidectomy using cartilage grafting.We conducted a retrospective case review.Tertiary referral center.A total of 95 patients (42 female, 53 male; 5-81 yr of age) with a recurrent perforation who were treated surgically with cartilage tympanoplasty without mastoidectomy were included in the chart review. Patients must have undergone at least one previous tympanoplasty without mastoidectomy and had to have complete audiologic and chart follow up.An underlay tympanoplasty technique using either a tragal cartilage-perichondrium island graft or palisaded concha cymba cartilage was used. Ossiculoplasty was performed as needed.Main outcome measures were incidence of reperforation of the grafted tympanic membrane, hearing result, and prevalence of other complications.Successful closure without reperforation was obtained in 90 of 95 patients (94.7%). Average postoperative pure-tone average air-bone gap was 12.2 +/-7.3 dB compared with 24.6+/-13.8 dB preoperatively (p <0.001).Revision tympanoplasty with cartilage provided equivalent results to tympanoplasty with mastoidectomy. Thus, mastoidectomy may not be necessary in revision tympanoplasty in the absence of cholesteatoma if the repair is made with cartilage.
Well-differentiated carcinoma of the thyroid. - Otolaryngologic clinics of North America
Thyroid cancer will be diagnosed in more than 20,000 individuals in the United States in 2002. Approximately 16,000 of these patients will be women. During the same year, an estimated 1300 deaths from thyroid cancer are expected. The various types of thyroid cancer include papillary carcinoma, follicular carcinoma, Hurthle cell carcinoma, medullary carcinoma, anaplastic carcinoma, and thyroid lymphoma. Papillary, follicular, and Hurthle cell carcinoma are considered well-differentiated thyroid cancers and constitute the focus of this article.

Map & Directions

5258 Dijon Dr Baton Rouge, LA 70808
View Directions In Google Maps

Nearby Doctors

7373 Perkins Rd Attn: Dee / Administration
Baton Rouge, LA 70808
225 694-4044
5339 Odonavan
Baton Rouge, LA 70808
225 664-4999
7777 Hennessy Blvd Suite 700
Baton Rouge, LA 70808
225 652-2048
3810 W Lakeshore Dr
Baton Rouge, LA 70808
225 788-8886
7373 Perkins Rd Attn: Camille/ Administration
Baton Rouge, LA 70808
225 694-4044
7777 Hennessy Blvd Suite 7000
Baton Rouge, LA 70808
225 658-8829
7301 Hennessy Blvd Ste 200
Baton Rouge, LA 70808
225 660-0050
7373 Perkins Rd
Baton Rouge, LA 70808
225 694-4044